Skip to content

Subscriptions are live.

Plans
Logo

Why is $KAPA stock down today?

Kairos Pharma, Ltd. · Pharmaceutical Preparations

Why is $KAPA down today?

The likely driver

Clinical / FDA update
Kairos Pharma, LTD.: Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer
SEC filing · Oct 6
Price
$0.74
Move today
-7.1%
Volume vs avg
0.0x
Scanner alerts today
0
Flagged in 30 days
70
Market cap
$3M
Prev close
$0.80
Avg volume
1.2M

Nothing has triggered on KAPA yet in this session. Our scanner has flagged it 70 times in the last 30 days , most recently on October 9 for trading halts, big percentage moves, halt resumes, which is why this page is here. See the full KAPA page for the chart and the alert history.

Earlier scanner activity on KAPA

  • Oct 9Unusual volume (RVOL) alert
  • Oct 9Unusual volume (RVOL) alert
  • Oct 9Unusual volume (RVOL) alert
  • Oct 9Unusual volume (RVOL) alert
  • Oct 9Big % mover alert
  • Oct 8Big % mover alert
  • Oct 8Unusual volume (RVOL) alert
  • Oct 8Unusual volume (RVOL) alert
  • Oct 8Unusual volume (RVOL) alert
  • Oct 8Unusual volume (RVOL) alert
  • Oct 8Unusual volume (RVOL) alert
  • Oct 8Watcher paper trade

Prior sessions in the last 30 days. A name our scanner keeps flagging is behaving differently from the rest of the market, even on a quiet day.

Free alerts

Get free $KAPA alerts the moment volume spikes

Be first to know when $KAPA makes an unusual move. Create a free account to track $KAPA, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.

Real-time RVOL & momentum alerts Personal watchlist & price alerts
Sign up free with email

No card · 5 premium days · join 800+ traders

Other stocks moving today

Each opens that stock’s own why-is-it-moving page.

Move and volume are based on the latest market data and refresh live on this page. Scanner alerts are our own real-time unusual-volume signals. This is research, not investment advice.